Collection is becoming more and more intense, a number of small and medium-sized pharmaceutical circulation enterprises will withdraw

Recently, after the results of the third batch of state-organized drug collection and selection were announced, Shanghai Sunshine Pharmaceutical Procurement Network released the third batch of state-owned distribution enterprises in Shanghai, from the public list, the third batch of state-owned distribution rights in Shanghai area are mainly divided by the drug and state control, has been difficult to find the figure of small and medium-sized distribution enterprises.
addition, in the first round of 4-7, the distribution of selected drugs in Shanghai is also by the two major pharmaceutical commercial companies of national medicine, medicine.
the reason why the centralized procurement of drugs organized by the state, distribution enterprises mainly to head drug dealers, mainly because of the national procurement of distribution enterprises put forward higher requirements.
such as designated distribution enterprises with 24 hours to the city's medical insurance fixed-point medical institutions to distribute the ability and conditions of selected drugs.
these conditions present considerable challenges to the cost control ability of pharmaceutical distribution enterprises.
background, the industry believes that survival will become the majority of circulation enterprises are currently facing a very big problem.
it requires the giant scale of pharmaceutical circulation enterprises, the centralized monopoly of the industry, the diversification of service capacity, intelligent feedback on supply chain management, cost control at the international level, and the formation of international mega-enterprises.
but it is worth noting that a number of small and medium-sized pharmaceutical circulation enterprises may therefore face an existential crisis.
As in the process of consolidation of commercial companies, the number of companies that have been revoked, written off, or closed down as a result of reduced business will gradually increase, and some agents may face the fate of being acquired, re-signed, or eliminated by upstream companies."
industry speculation, in many "drug intermediaries" will withdraw from the pharmaceutical industry, the concentration of the industry will be higher and higher background.
2020, the concentration of the pharmaceutical distribution industry will rise from the current 30% to 70%.
addition, the market is also expected to quickly concentrate on several major pharmaceutical circulation enterprises in the hands of leaders.
in fact, the current pharmaceutical circulation enterprises have begun to lay out.
Such as large-scale domestic private pharmaceutical commercial enterprises, Kyusju Tong Group as early as 2008-2010 in the three-year plan, mentioned the plan to gradually establish 15 subsidiaries, 100 secondary distribution centers, 5000 retail chain stores, occupy 10% of the country's market share, to achieve annual sales revenue of more than 30 billion yuan.
And on September 9 last year, Nanjing Pharmaceuticals also announced that, in order to further focus on the company's drug circulation business development, improve the overall business network construction in Jiangsu, improve the market coverage capacity of Xuzhou region, the company and Jiangsu Enhua Pharmaceuticals and natural person Chen Support signed a "letter of intent" on the company's acquisition of Enhua Pharmaceuticals commercial holding subsidiary Jiangsu Enhua and Run Pharmaceutical equity related matters reached a preliminary consensus.
, with the expansion of the scope of centralized procurement of drugs, as well as the corresponding regulatory documents, drug distribution enterprises market concentration is indeed being further improved.
the future, driven by various policies, will continue to accelerate the industry to speed up the reshuffle, integration of the general trend.
in the fierce market competition, will lead to pharmaceutical circulation enterprises through mergers and reorganization of the extended growth and actively develop end-market end-type growth, to enhance their own strength.
This is very beneficial to the development and growth of leading enterprises, but for some small and medium-sized pharmaceutical circulation enterprises, the future will be under greater pressure, and under this pressure, a number of small and medium-sized pharmaceutical circulation enterprises will accelerate the exit.